Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Polymyalgia rheumatica].

M Nishikai1

  • 1Department of Internal Medicine, National Tokyo Medical Center.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 17, 1999
PubMed
Summary
This summary is machine-generated.

Polymyalgia rheumatica (PMR) causes severe muscle pain and stiffness, particularly in the shoulders and hips. Early steroid treatment is effective, with higher doses needed if temporal arteritis is also present.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders.

Rheumatology (Oxford, England)·2001
Same author

[Clinical significance of magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults].

Ryumachi. [Rheumatism]·2001
Same author

[Fibromyalgia].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·1999
Same author

Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen.

British journal of rheumatology·1998
Same author

Incidence of antinuclear antibodies in Japanese patients with chronic fatigue syndrome.

Arthritis and rheumatism·1997
Same author

'Seronegative' Sjögren's syndrome manifested as a subset of chronic fatigue syndrome.

British journal of rheumatology·1996
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Context:

  • Polymyalgia rheumatica (PMR) is an inflammatory condition affecting older adults.
  • Characterized by proximal muscle stiffness and pain, normal creatine kinase, and elevated erythrocyte sedimentation rate.
  • A significant subset of PMR patients (10-50%) also present with concomitant temporal arteritis (TA), also known as giant cell arteritis.

Purpose:

  • To outline the key diagnostic features of Polymyalgia Rheumatica.
  • To discuss differential diagnoses including rheumatoid arthritis, polymyositis, fibromyalgia, malignancies, infections, and depression.
  • To differentiate treatment strategies based on the presence or absence of concomitant temporal arteritis.

Summary:

  • PMR presents with severe shoulder and pelvic girdle myalgia and stiffness, typically with acute onset in the elderly and elevated ESR.

Related Experiment Videos

  • Normal serum creatine kinase levels are a hallmark, distinguishing it from other myopathies.
  • Treatment involves corticosteroids: low-dose (15-20 mg/day prednisolone) for PMR alone, and high-dose (40-60 mg/day prednisolone) or pulse therapy for PMR with TA.

    • Impact:

    • Accurate diagnosis and tailored steroid therapy are crucial for effective management of PMR and its potential complication, TA.
    • Understanding the distinction in treatment intensity based on TA presence optimizes patient outcomes and minimizes steroid-related side effects.
    • This approach aids clinicians in managing PMR, a common cause of inflammatory symptoms in the elderly.